| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 23 May 2025 | 16 May 2025 |
| Concord Drugs Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2025 inter alia to consider and approve Audited Results for Quarter and Financial Year ending March 31st 2025. Board of Directors have approved Audited Financial Results for Quarter and Year ending 31st March,2025 in Board Meeting held. (As Per BSE Announcement Dated on: 23/05/2025) | ||
| Board Meeting | 17 Mar 2025 | 4 Mar 2025 |
| Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/03/2025 inter alia to consider and approve Increase in Authorised Capital of the company Fund raising by way of preferential issue of shares and warrants etc and other items. Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/03/2025 ,inter alia, to consider and approve 1. Increase in Authorised Capital 2. Issue of shares on Preferential Allotment 3. Any other matter with the permission of chair. (As Per BSE Announcement Dated on: 13/03/2025) Outcome of Board Meeting (As Per BSE Announcement Dated on: 17/03/2025) | ||
| Board Meeting | 11 Jan 2025 | 7 Jan 2025 |
| Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/01/2025 inter alia to consider and approve Un-Audited Financial Results of 31st December 2024 Company has approved its financial results for quarter ended 31 December, 2024 in its Board Meeting held on 11 Janaury 2025. Outcome of Board Meeting (As per BSE Announcement Dated on 11/01/2025) | ||
| Board Meeting | 13 Nov 2024 | 6 Nov 2024 |
| Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2024 inter alia to consider and approve Un-audited Financials for quarter ended 30th Sep 2024 Financial Results for Q2 ending 30 September 2024 (As Per Bse Announcement Dated on 13.11.2024) | ||
| Board Meeting | 6 Sep 2024 | 2 Sep 2024 |
| Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/09/2024 inter alia to consider and approve Increase in Authorized Capital Proposal for Issue of Preferential Issue of Shares Other business if any. Out Come of Board Meeting . (As Per BSE Announcement Dated on: 06/09/2024) | ||
| Board Meeting | 9 Aug 2024 | 3 Aug 2024 |
| Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2024 inter alia to consider and approve Concord Drugs Ltd has informed BSE that the meeting of the Board of directors Meeting is scheduled on 09th August 2024 for Approval of Unaudited(Standalone & Consolidated) Financial Results for 1st Quarter 2024 and to consider any other matter by permission of Chair Submission of Financial Results for Quarter ended 30.06.2024 Submission of financial results for year/quarter ended 31.03.2024 after rectification . (As Per BSE Announcement Dated on: 08/08/2024) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.